At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 25 enrolled
Drug / intervention
autologous muscle-derived cells (AMDC)biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Muscle Cell Mediated Therapy for Stress Urinary Incontinence in Males Following Prostate Surgery: An Investigation of Cook MyoSite Autologous Muscle Derived Cells
In Brief
A Phase 2 clinical trial evaluating autologous muscle-derived cells (AMDC) for Urinary Incontinence and 5 related conditions. Completed, enrolled 25 participants across 5 sites.
Detailed Summary
To study the safety and potential efficacy of Autologous Muscle Derived Cells for Urinary Sphincter Repair (AMDC-USR) for the treatment of male stress urinary incontinence (SUI) for patients that have undergone prior prostate surgery.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUrinary Incontinence, Stress, Urination Disorders, Urologic Diseases, Lower Urinary Tract Symptoms, Urological Manifestations
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedNov 2014
Enrollment StartFeb 2015
Primary CompletionJun 2019
TodayJul 2026
First PostedNov 14, 2014
Enrollment StartFeb 19, 2015
Primary CompletionJun 28, 2019
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 11.6 years ago
Interventions
autologous muscle-derived cells (AMDC)biological
Cell treatment